Mixed views on Broad’s fate after EPO revokes CRISPR patent
Commentators have offered differing opinions on the impact of yesterday’s decision by the European Patent Office (EPO) to revoke a CRISPR/Cas9 patent owned by the Broad Institute of Harvard and MIT.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
5 February 2026 Excitement is mounting for the world’s largest IP gathering, which will see the industry’s elites travelling to the UK in the spring, reveals the association’s CEO.
3 February 2026 As legislative activity in life sciences increases, in-house teams are struggling to keep up. Experts share their sources and strategies for monitoring developments, coordinating internally, and knowing when to engage.
16 January 2026 A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.